Evidence map›Paper›PMID 42699204›Full record

ReviewNew microbes and new infections2026

Colombian protocol for the hospital management of non-critically ill patients with suspected or confirmed yellow fever.

Diana Alejandra Hernández-Ramírez, Iván Darío Gutiérrez-Castillo, Álvaro A Faccini-Martínez, Leidy J Medina-Lozano, Yeh-Li Ho, Wilmer E Villamil-Gómez, Abraham Katime-Zuñiga, Edwin Alberto Torres-García, Sergio Andrés Cruz-Vargas, Juan Carlos Mahecha-Ramírez and 4 more

Abstract readReview
In one paragraph

Review in New microbes and new infections, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Diana Alejandra Hernández-RamírezService of Internal Medicine-Research Line IMPACTA-Salud, Hospital Federico Lleras Acosta, Ibagué, Tolima, Colombia.
Iván Darío Gutiérrez-CastilloService of Internal Medicine-Research Line IMPACTA-Salud, Hospital Federico Lleras Acosta, Ibagué, Tolima, Colombia.
Álvaro A Faccini-MartínezServicio de Infectología, Hospital Militar Central, Bogotá, D.C., Colombia.
Leidy J Medina-LozanoPrograma de Especialización en Infectología, Universidad Nacional de Colombia, Bogotá, D.C., Colombia.
Yeh-Li HoDepartment of Infectious Diseases and Tropical Medicine, School of Medicine, University of São Paulo, Brazil.
Wilmer E Villamil-GómezCentro de Investigación en Ciencias de la Vida, Universidad Simón Bolívar, Barranquilla, Colombia.
Abraham Katime-ZuñigaComité de Medicina Tropical, Zoonosis y Medicina del Viajero, Asociación Colombiana de Infectología (ACIN), Bogotá, D.C., Colombia.
Edwin Alberto Torres-GarcíaService of Internal Medicine-Research Line IMPACTA-Salud, Hospital Federico Lleras Acosta, Ibagué, Tolima, Colombia.
Sergio Andrés Cruz-VargasService of Internal Medicine-Research Line IMPACTA-Salud, Hospital Federico Lleras Acosta, Ibagué, Tolima, Colombia.
Juan Carlos Mahecha-RamírezService of Internal Medicine-Research Line IMPACTA-Salud, Hospital Federico Lleras Acosta, Ibagué, Tolima, Colombia.
Zully Adriana Chaparro-QuinteroService of Internal Medicine-Research Line IMPACTA-Salud, Hospital Federico Lleras Acosta, Ibagué, Tolima, Colombia.
Raúl Ricardo Torres-LlanosService of Internal Medicine-Research Line IMPACTA-Salud, Hospital Federico Lleras Acosta, Ibagué, Tolima, Colombia.
Danna Lucía Calderón-MedinaService of Internal Medicine-Research Line IMPACTA-Salud, Hospital Federico Lleras Acosta, Ibagué, Tolima, Colombia.
Alfonso J Rodríguez-MoralesFaculty of Health Sciences, Universidad Cientifica de Sur, Lima, Peru.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Yellow fever (YF) continues to cause high lethality in Colombia; timely, standardized care is critical. This guideline consolidates current evidence and frontline experience to support hospital management of non-critically ill patients with YF. It introduces an operational five-group classification (A, B1, B2, C1, C2) to guide level of care, monitoring, and escalation, complemented by NEWS2 and West Haven scores to help judgment. Recommendations cover initial assessment; laboratory tests and imaging; restriction of fluids; bleeding risk mitigation with transfusion thresholds; avoidance of hepatotoxic and nephrotoxic medications; measures to prevent mosquito exposure; and criteria for safe discharge (after 7 days from symptom onset and >72 h of fever-free status). The protocol emphasizes differential diagnosis with other etiologies of tropical/endemic fever and defines post-discharge surveillance to detect late-onset hepatitis and persistent progressive jaundice. Developed by a multidisciplinary team and endorsed by scientific societies, this context-adapted guidance aims to significantly reduce morbidity and mortality in endemic settings.

Indexed as

ColombiaEpidemicHospitalization managementProtocolYellow fever

Identifiers

PMID42699204
PMCPMC13544106

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.